BBNX
Beta Bionics, Inc.Company Information
- Company Name
- Beta Bionics, Inc.
- CIK
- CIK0001674632
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BBNX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- BBNX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-31
- Last sale
- 2026-09-22
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 248,318
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 48,175,142
- Shares outstanding
- 44,545,293
- Ownership
- 108.15%
Earnings Market Reaction
- Filing date
- 2026-07-29
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Class A | - | - | - | 0 | 0 | 0 | 0 | ||||||
Assets | |||||||||||||
| Cash And Cash Equivalents At Carrying Value | 44 | 30 | 32 | 38 | 35 | 42 | 30 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | - | - | - | - | ||||||
| Short Term Investments | 136 | 169 | 188 | 190 | 215 | 189 | 73 | ||||||
Assets Current | |||||||||||||
| Assets Current | 231 | 248 | 268 | 270 | 286 | 262 | 133 | ||||||
| Accounts Receivable Net Current | 18 | 16 | 17 | 12 | 11 | 9 | 12 | ||||||
| Inventory Net | 24 | 24 | 22 | 20 | 17 | 16 | 13 | ||||||
| Prepaid Expense And Other Assets Current | 8 | 9 | 10 | 9 | 8 | 6 | 4 | ||||||
| Property Plant And Equipment Net | 11 | 10 | 9 | 7 | 6 | 6 | 5 | ||||||
| Operating Lease Right Of Use Asset | 6 | 6 | 7 | 7 | 6 | 6 | 7 | ||||||
| Restricted Cash Noncurrent | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | 5 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 321 | ||||||
| Long Term Investments | 45 | 40 | 45 | 45 | 31 | 64 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 292 | 304 | 329 | 330 | 330 | 338 | 150 | ||||||
Liabilities | |||||||||||||
| Accounts Payable Current | 5 | 2 | 5 | 4 | 3 | 3 | 3 | ||||||
| Accrued Liabilities And Other Liabilities | 17 | 17 | 22 | 18 | 13 | 11 | 16 | ||||||
Liabilities Current | |||||||||||||
| Liabilities Current | 26 | 23 | 31 | 25 | 19 | 16 | 21 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deferred Revenue Current | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 5 | 6 | 5 | 5 | 6 | ||||||
| Deferred Revenue Noncurrent | 3 | 3 | 3 | 3 | 3 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 1 | 1 | - | - | ||||||
| Liabilities | 36 | 33 | 41 | 35 | 28 | 24 | 74 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 672 | 663 | 657 | 651 | 644 | 639 | 51 | ||||||
Stockholders Equity | |||||||||||||
| Stockholders Equity | 256 | 271 | 288 | 295 | 302 | 314 | -245 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -415 | -392 | -370 | -356 | -342 | -325 | -297 | ||||||
| Liabilities And Stockholders Equity | 292 | 304 | 329 | 330 | 330 | 338 | 150 | ||||||
| Common Class B | - | - | 4 | 0 | -4 | 4 | 0 | ||||||
| Common Class C | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | 0 | 0 | 0 | 0 | 35 | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 0 | 17 | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | 0 | 0 | 0 | 17 | ||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | 0 | 355 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | - | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 700 | 700 | 700 | 700 | 700 | 700 | 700 | ||||||
| Common Stock Shares Issued | 45 | 45 | 44 | 44 | 43 | 43 | 7 | ||||||
| Shares Outstanding | 45 | 45 | 44 | 44 | 43 | 43 | 7 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBeta Bionics, Inc. (BBNX) — SEC Financial Statements & Analysis
Beta Bionics, Inc. (BBNX) is a surgical & medical instruments & apparatus company, incorporated in DE. Beta Bionics, Inc. trades on Nasdaq as: BBNX. Beta Bionics, Inc. (BBNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, Beta Bionics, Inc. carries a market cap of $698.02M, a P/E ratio of -9.57x, a P/B ratio of 2.72x, a P/S ratio of 5.87x, an enterprise value of $653.61M, and an EV/EBITDA multiple of -8.09x. On profitability, it posts a gross margin of 58.31%, an operating margin of -69.75%, a net margin of -61.32%, a Return on Equity (ROE) of -26.16%, a Return on Assets (ROA) of -23.45%, and a Return on Invested Capital (ROIC) of -34.53%. Per share, it reports EPS of $-1.64, diluted EPS of $-1.64, free cash flow per share of $-1.38, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 8.88x, a quick ratio of 7.64x, working capital of $205.02M, a debt-to-equity ratio of 0.14x, a debt ratio of 0.12, free cash flow of $-61.41M (TTM), and net debt of $-44.42M. Figures sourced from SEC EDGAR.
- Market Cap
- $698.02M
- P/E TTM
- -9.57x
- EPS TTM
- $-1.64
- P/B TTM
- 2.72x
- ROE TTM
- -26.16%
- ROA TTM
- -23.45%
- Debt To Equity
- 0.14x
- Free Cash Flow TTM
- $-61.41M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Beta Bionics, Inc. in?
Beta Bionics, Inc. (BBNX) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does BBNX trade on?
Beta Bionics, Inc. (BBNX) trades on the Nasdaq.
Where is Beta Bionics, Inc. incorporated?
Beta Bionics, Inc. is incorporated in DE.
When was Beta Bionics, Inc. (BBNX)'s most recent SEC filing?
Beta Bionics, Inc. (BBNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29.
What is BBNX's market cap?
Beta Bionics, Inc. (BBNX) has a market capitalization of $698.02M as of 2026-06-30.
What is BBNX's EPS (earnings per share)?
Beta Bionics, Inc. (BBNX)'s trailing twelve month EPS is $-1.64 as of 2026-06-30.
What is BBNX's ROE (return on equity)?
Beta Bionics, Inc. (BBNX)'s trailing twelve month Return on Equity (ROE) is -26.16% as of 2026-06-30.
What is BBNX's ROA (return on assets)?
Beta Bionics, Inc. (BBNX)'s trailing twelve month Return on Assets (ROA) is -23.45% as of 2026-06-30.
What is BBNX's ROIC (return on invested capital)?
Beta Bionics, Inc. (BBNX)'s trailing twelve month Return on Invested Capital (ROIC) is -34.53% as of 2026-06-30.
What is BBNX's EV/EBITDA?
Beta Bionics, Inc. (BBNX)'s trailing twelve month EV/EBITDA is -8.09x as of 2026-06-30.